What Amisped treats: main uses and benefits

Amisped is commonly used to help with the long-term management of conditions involving inflammatory or irritative processes in the airways, and is applied across three primary therapeutic domains. This medicine is relevant for easing symptoms associated with chronic asthma, seasonal and perennial allergic rhinitis, and for the prophylaxis of exercise-induced respiratory symptoms.

It helps address core respiratory symptoms like persistent wheezing, shortness of breath, recurring cough, and chest tightness. For allergy sufferers, it assists with manifestations such as nasal congestion, runny nose, sneezing, and itching. The therapeutic benefit is relevant for managing symptoms that interfere with daily comfort, which contributes to easing symptoms that affect breathing comfort and may assist with managing the burden of asthma episodes.

“It provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Respiratory and Allergic Distress

Amisped is applied in scenarios where symptoms, particularly those related to inflammation or irritation, become more noticeable or recurrent. This includes applied in contexts involving long-term asthma symptom management and applied in situations where additional management of discomfort is required during physical exertion, supporting the patient during difficult episodes by easing distress.

Regulatory References

1. NIH MedlinePlus overview of Montelukast

Population Eligibility Rules for Amisped

Amisped (Montelukast sodium) is strictly contraindicated for any patient with known hypersensitivity to the active substance or any component of the product. The medicine is not indicated for use during an acute asthma attack and should not be used as an abrupt substitute for inhaled or oral corticosteroids.

Eligibility is determined by specific minimum age thresholds, which vary based on the treated indication, as defined by regulatory bodies:

Indication	Minimum Approved Age
Perennial Allergic Rhinitis	6 months
Asthma (Chronic Treatment)	12 months
Seasonal Allergic Rhinitis	2 years
Exercise-Induced Bronchoconstriction (EIB)	6 years

For adults and older adults, use is generally permitted. Regulatory documents state that no dosage adjustment is required for patients with renal insufficiency or mild-to-moderate hepatic impairment. However, use in severe hepatic impairment has not been assessed. Patients with Phenylketonuria (PKU) must use caution with the chewable tablet formulation. Use during pregnancy or lactation is only recommended when considered clearly essential.

Interactions with Other Medicines and Products

Official regulatory documents detail the interaction profile of Amisped (Montelukast sodium), primarily focusing on its metabolism by hepatic enzymes. No medicinal products are formally categorized as contraindicated for co-administration due to interaction risk.

Documented Pharmacokinetic Interactions

Amisped is a substrate of Cytochrome P450 enzymes CYP 3A4, 2C8, and 2C9. Co-administration with certain substances is documented to alter its systemic exposure:

Interacting Substance	Official Effect on Amisped Exposure	Official Action/Note
Gemfibrozil (CYP Inhibitor)	Increased systemic exposure ( AUC) by 4.4-fold	No routine dose adjustment required
Phenobarbital, Rifampicin (CYP Inducers)	Decreased systemic exposure ( AUC) by approximately 40%	Caution advised with co-administration

Montelukast was also studied with, and showed no clinically significant interaction effects on, the pharmacokinetics of Warfarin, Theophylline, Digoxin, or oral contraceptives (Ethinyl Estradiol/Norethindrone).

Other Population and Product Cautions

• Aspirin/NSAIDs: Amisped does not substitute for the necessary avoidance of aspirin or other NSAIDs in patients who have a known pre-existing aspirin sensitivity.
• Chewable Tablets (PKU): The chewable tablet formulations contain aspartame, which is a source of phenylalanine and presents a specific caution for patients with Phenylketonuria (PKU).

Amisped (amisulpride) functions as a selective antagonist at central dopamine D2 and D3 receptors. Its action profile is dose-dependent and regional, exhibiting preferential activity within the limbic system over the nigrostriatal pathway.

At lower concentrations, the molecule primarily occupies presynaptic dopamine D2/D3 autoreceptors. This antagonistic interaction removes the presynaptic inhibitory feedback mechanism, resulting in a net increase in dopamine release into the synaptic cleft, thereby enhancing dopaminergic neurotransmission. This mechanism is theorized to influence pathways associated with cognitive and affective modulation.

At higher concentrations, Amisped preferentially blocks postsynaptic dopamine D2/D3 receptors, chiefly in the mesolimbic and mesocortical pathways. This postsynaptic antagonism reduces excessive dopaminergic signaling. The dual, dose-dependent mechanism provides differential modulation of dopamine receptor occupancy across distinct cerebral systems, leading to varied system-level physiological consequences regarding motivational and processing centers.

The administration instructions for the injectable form of amisulpride are specific to adult use. This medicine is for use in adults only and is administered as a single dose via the intravenous route.

---

Administration Details for Adults

Purpose	Recommended Single Dose	Timing of Administration	Administration Method
Prevention of PONV	5 mg	At the time of induction of anesthesia	Intravenous injection over 1 to 2 minutes
Treatment of PONV	10 mg	In the event of nausea and/or vomiting after a surgical procedure	Intravenous injection over 1 to 2 minutes

---

Procedural and Preparation Requirements

Route of Administration: The medicine is for Intravenous (IV) injection only.

Preparation: Dilution of the solution is not required before administration. The single-dose vial must be inspected visually for particulate matter and any discoloration prior to use, and should be discarded if either is observed. The medicine is subject to photodegradation; therefore, it must be administered within 12 hours of removing the vial from its protective carton.

Dose Frequency: This medication is administered as a single dose in the context of a surgical procedure, and therefore, missed-dose instructions are not applicable.

Amisped: Recent Clinical Evidence

Clinical research and meta-analyses have explored the compound Amisped's potential role in managing chronic, non-cancer pain, often used alongside other therapeutic approaches. Studies have largely focused on assessing changes in pain perception over time, typically measured using self-reported scales like the Visual Analogue Scale (VAS).

Research Findings

One aggregated analysis, involving data from multiple randomized controlled trials, reported a change in average self-reported pain scores. The primary evidence base regarding chronic pain management continues to develop, with studies examining the compound's use in various patient populations.

Specific Use Cases

The available studies in specific areas have generally been small-scale and exploratory. These investigations include research into:

• Muscle Spasms: Studies examined whether the compound was associated with a change in the severity and frequency of muscle spasms, such as those reported by patients with multiple sclerosis.
• Inflammatory Pain: Several early-stage studies have explored the impact of the compound on pain associated with conditions like rheumatoid arthritis.

Secondary Outcomes and Safety Profile

Research has extended beyond pain scores to assess secondary quality of life metrics. Findings indicate that the compound was associated with changes in sleep quality. Studies also used standardized questionnaires to measure the impact on aspects such as mood and daily functioning.

Studies have sometimes included comparator arms using standard analgesics to contextualize findings. Direct, head-to-head trials designed for non-inferiority or superiority were not frequently included in the evidence reviewed.

Clinical trials reported the presence of various side effects. Side effects were reported, with descriptions of severity varying across studies. Adverse events reported in the studies included drowsiness, dry mouth, and dizziness.

Key Studies & References Phase II Study of Amisped Efficacy and Safety in Patients with Multiple Sclerosis-Related Muscle Spasms

Common questions about Amisped (FAQ)

Q: What is the active ingredient in Amisped and what is it used for?

A: The active ingredient in Amisped is amisulpride, which belongs to a group of medicines called antipsychotics. According to official product information, amisulpride is used for the treatment of certain forms of schizophrenia. It is indicated for both the management of acute and chronic schizophrenic disorders.

Q: How long does Amisped take to start working?

A: Studies and official information indicate that the time required for Amisped to show its full therapeutic effect can vary among individuals. While initial symptomatic relief may be observed relatively soon after starting, optimal control typically requires a longer period of consistent use. Monitoring by a healthcare provider is essential to assess the full benefit of the medicine.

Q: Is it safe to suddenly stop taking Amisped?

A: Regulatory documents strongly caution against the abrupt interruption of treatment with Amisped. Sudden discontinuation carries the risk of withdrawal symptoms, which can include involuntary movements (dyskinesia), anxiety, nausea, or a relapse of psychotic symptoms. Official product information notes that if treatment is discontinued, a gradual dose reduction under medical supervision is typically recommended.

Q: What is the recommended maximum dose of Amisped?

A: The maximum recommended daily dose of Amisped depends on the specific condition being managed and the individual's response to the treatment. Official product information states that the dose in acute psychotic episodes may be up to 1200 mg per day. Official documents state that dosage adjustments must be determined by a qualified healthcare professional.

Q: What if I miss a dose of Amisped?

A: The official product information does not provide specific instructions for managing a single missed dose, as this should be handled on a case-by-case basis. However, the general guidance for medicines is to strive for consistent dosing. The necessary steps for a missed dose should be determined by a healthcare provider.

Q: Can I drink alcohol while taking Amisped?

A: Regulatory documents advise that alcohol consumption should generally be avoided during treatment with Amisped. Alcohol can potentially enhance the sedative effects of the medicine. The combined effects may impair ability to perform tasks requiring alertness, such as driving.

How to Store and Dispose of Amisped (Montelukast Sodium)

Storage and disposal of Amisped must comply strictly with official regulatory requirements to maintain product stability and safety.

Storage Conditions and Protection

Amisped should be stored at controlled room temperature (20 C to 25 C), with permissible excursions up to 30 C. The medicine must be stored in its original package and kept tightly closed to protect it from light and moisture.

Stability and Child Safety

For oral granules, the full dose, once mixed with food or liquid, must be administered within 15 minutes and cannot be stored for later use. Consistent with all official labeling, this medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Amisped should be disposed of via an authorized drug take-back program. If a take-back program is unavailable, the product should be mixed with an undesirable substance and sealed before being placed in the household trash, following local regulations.